Halozyme Therapeutics/$HALO
1D1W1MYTD1Y5YMAX
Capital at risk
About Halozyme Therapeutics
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.
- Ticker
- $HALO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 423
- Headquarters
- San Diego, United States
- Website
- halozyme.com
HALO Metrics
BasicAdvanced
$13B
33.25
$3.38
0.88
-
Price and volume
Market cap
$13B
Beta
0.88
52-week high
$116.85
52-week low
$61.23
Average daily volume
2.1M
Financial strength
Current ratio
2.709
Quick ratio
1.994
Long term debt to equity
13.721
Total debt to equity
15.177
Interest coverage (TTM)
46.52%
Profitability
EBITDA (TTM)
1,050.688
Gross margin (TTM)
76.27%
Net profit margin (TTM)
24.86%
Operating margin (TTM)
56.77%
Effective tax rate (TTM)
29.10%
Revenue per employee (TTM)
$3,930,000
Management effectiveness
Return on assets (TTM)
25.49%
Return on equity (TTM)
173.67%
Valuation
Price to earnings (TTM)
33.245
Price to revenue (TTM)
7.945
Price to book
89.33
Price to tangible book (TTM)
-9.42
Price to free cash flow (TTM)
25.495
Free cash flow yield (TTM)
3.92%
Free cash flow per share (TTM)
4.41
Growth
Revenue change (TTM)
41.15%
Earnings per share change (TTM)
-22.52%
3-year revenue growth (CAGR)
29.08%
10-year revenue growth (CAGR)
27.30%
3-year earnings per share growth (CAGR)
25.71%
10-year earnings per share growth (CAGR)
20.52%
What the Analysts think about HALO
Analyst ratings (Buy, Hold, Sell) for Halozyme Therapeutics stock.
Analyst projections of the future price of Halozyme Therapeutics stock.
Bulls say / Bears say
Halozyme’s Q2 2026 non-GAAP EPS of $2.28 significantly beat the IBES consensus of $1.84, demonstrating strong operational leverage (Reuters)
Second-quarter revenue surged 48% year-over-year to $481 million, prompting management to raise full-year 2026 guidance across revenue, royalties, EBITDA and EPS (Reuters)
Royalty revenue reached a record $307.7 million, up 50% year-over-year, reflecting robust uptake of ENHANZE-enabled subcutaneous formulations across multiple partner drugs (Reuters)
Ongoing patent litigation with Merck in the U.S. and abroad poses potential revenue risks and could result in substantial legal costs or unfavorable licensing terms (Reuters)
Research and development and sales, general & administrative expenses rose to $27.7 million and $57 million respectively in Q2, which may pressure margins if cost growth outpaces revenue (Reuters)
Despite diversification efforts, Halozyme’s royalty portfolio remains concentrated, with a handful of products still driving the majority of revenue, increasing vulnerability to partner execution risk (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 3 Sept 2026.
HALO Financial Performance
Revenues and expenses
HALO Earnings Performance
Company profitability
Upcoming events
No upcoming events
HALO News
AllArticlesVideos
Funds containing HALO
AllUSDEURGBP
Fund name | Fund size | $HALO weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 1.38% |
iShares Healthcare Innovation€2B78 | €1.2B | 1.38% |
iShares Healthcare Innovation£DRDR | £1B | 1.38% |
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.85% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.85% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.